TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

NetDania - New 12 months Low: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

10 Apr 2025 12:37:35 By NetDania Notify

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

07 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

07 Apr 2025 07:30:52 By Nasdaq GlobeNewswire

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

31 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

27 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Teva Releases Q1 2025 Aide Memoire

27 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

03 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

27 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

25 Feb 2025 16:00:00 By Nasdaq GlobeNewswire

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

22 Feb 2025 02:20:00 By Nasdaq GlobeNewswire

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

21 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

18 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

18 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

29 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

27 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

13 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

10 Jan 2025 08:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

26 Dec 2024 10:39:11 By NetDania Notify

NetDania - New 12 months High: TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DE

24 Dec 2024 09:45:03 By NetDania Notify

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23 Dec 2024 16:30:00 By Nasdaq GlobeNewswire